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ABSTRACT:
The inhibition of tumor angiogenesis is one of the main challenges in cancer 
therapy. With the aim of developing monoclonal antibodies able to inhibit angiogenesis, 
we immunized mice with proliferating human umbilical vein endothelial cells. We 
generated a library of monoclonal antibodies able to recognize antigens expressed 
on endothelial cells and screened the antibodies for their ability to inhibit endothelial 
cell proliferation, migration, and sprouting in vitro. Here, we show that the antibody, 
designated as 4E1, is able to neutralize the formation of new vessels both in vitro and 
in vivo without affecting endothelial cell survival. By mass spectrometry we identified 
CD93 as the antigen bound by 4E1 and mapped the recognized epitope. CD93 is a 
transmembrane protein heavily glycosylated preferentially expressed in the vascular 
endothelium. CD93 silencing by lentiviral-mediated small hairpin RNA expression 
impairs human endothelial cell proliferation, migration, and sprouting. Altogether 
these findings reveal 4E1 as a novel antiangiogenic antibody and identify CD93 as a 
new target suitable for antiangiogenic therapy.
INTRODUCTION
Angiogenesis supplies all cellular tissues with 
oxygen and nutrients and plays a key role not only 
during embryo development and physiologic processes 
but also in several diseases, of which cancer is perhaps 
the most serious [1, 2]. Since without blood vessels 
tumors cannot grow beyond a critical size or metastasize 
to distant organs, it appeared immediately evident that 
suppression of angiogenesis could be a valid strategy for 
the development of anticancer treatments. Thus, in recent 
years angiogenesis inhibitors have been developed and 
approved for a wide range of cancer types [3]. Among 
them, monoclonal antibodies (mAbs) revealed useful 
tools for cancer treatment [3, 4]. Bevacizumab (Avastin, 
Genentech/Roche), a function-blocking antibody to VEGF, 
was the first to show clinical benefit in patients with 
colorectal cancer when combined with chemotherapy [5]. 
However, the use of this drug combination highlighted that 
antiangiogenic therapy is hampered by reactive resistance-
response of cancer cells and Bevacizumab can function by 
either blocking this resistance-response or by normalizing 
tumor angiogenesis allowing a better drug delivering to 
tumor cells [6]. Thus, despite the use of antiangiogenic 
strategies has proved successful for some patients, 
antiangiogenic therapy still needs to improve efficacy, 
avoid resistance, and minimize toxicity [7-9]. Antigens 
involved in angiogenesis that are suitable for antibody-
based therapeutics are usually proteins that support the 
formation of new vasculature, such as the growth factors 
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belonging to the VEGF family [10, 11]. However, 
the discovery of new antigens with complementary 
functions, could offer novel opportunities for improved 
treatment.
In the present study, exponentially growing 
endothelial cells were used to generate a novel murine 
IgG1 antibody, 4E1, which revealed able to inhibit 
angiogenesis both in vitro and in vivo experiments. 
Biochemical analyses showed that CD93 is the antigen 
recognized by 4E1 and deletion mutant analyses mapped 
the binding site of 4E1 on CD93 extracellular domain. 
Human CD93 is a cell surface glycoprotein 
composed of 652 amino acids. The predicted molecular 
mass of CD93 is 68 kDa, but its relative migration in 
SDS-PAGE under reducing conditions is 126 kDa due 
to a high degree of glycosylation and the presence of 
regions with high contents of proline and charged amino 
acids [12-14]. The structural domain analysis within 
CD93 from N- to C-terminus reveals the presence of 
a C-type lectin-like domain (CTLD), five epidermal 
growth factor (EGF)-like repeats, a mucin-like domain, a 
transmembrane domain, and a cytoplasmic domain [12]. 
Accordingly to Wu and colleagues [15], these domains 
were respectively designated as D1, D2, D3, D4, and 
D5, while we designated DX a 79-amino acid domain of 
unknown structural function localized between D1 and 
D2 domains. 
Many evidences suggest that CD93 may play 
a role in the endothelium. Although human CD93 is 
expressed in different cellular types, its predominant 
site of expression is the vascular endothelium [16-18]. 
The mouse homologue of CD93, AA4, is expressed on 
vascular endothelial cells in the developing embryo, 
particularly during the remodeling of blood vessels, 
consistent with a role for CD93 in angiogenesis [19]. 
Moreover, the surface protein CD93 is susceptible to 
protein ectodomain cleavage, or shedding, that may 
contribute to the angiogenic process [20]. Indeed, 
recently it has been reported that the soluble EGF-like 
domain of CD93 is a novel angiogenic factor [15]. 
However, despite these observations the molecular 
function of CD93 in angiogenesis must still be clarified.
Here, using an anti-CD93 monoclonal antibody 
and inhibiting the function of CD93 in human endothelial 
cells, we demonstrate the involvement of CD93 in the 
control of endothelial cell function and identified a 
potential new target for antiangiogenic treatment of 
diseases.
RESULTS
The mAb 4E1 inhibits in vitro and in vivo 
angiogenesis
Angiogenesis involves both proliferation and 
migration of capillary endothelial cells. Since cycling 
endothelial cells express a different antigen profile 
compared to quiescent cells found in stable vessels [21, 
22], we immunized mice with proliferating HUVEC 
to raise mAbs able to block the function of proteins 
involved in the angiogenic process. First, we screened 
antibodies able to selectively recognized antigens on 
the surface of endothelial cells by flow cytometry 
(Supplemental Fig. 1). Then, we purified these mAbs and 
used them to challenge the main traits of the angiogenic 
process: proliferation, migration, and differentiation. 
We selected the mAb 4E1 (isotype IgG1, k chain) that 
revealed to be competent for the inhibition of HUVEC 
proliferation in a dose-dependent manner, whereas an 
unrelated antibody did not influence cell proliferation 
Figure 1: The mAb 4E1 affects cell proliferation, 
migration, and in vitro sprouting of human 
endothelial cells. A: Cell proliferation expressed as 
thymidine uptake in HUVEC. Cells were grown in 96-well-
plates, serum starved, and induced to proliferate with complete 
medium (induct.) in the presence of different concentrations 
of 4E1 or unrelated purified antibodies (NC, 500 nM). B: 
Migration assay on HUVEC in the presence of 4E1 (500 nM) 
or unrelated purified antibodies (NC, 500 nM). Cells were 
grown in growth factor-depleted culture medium and plated 
in Boyden chambers. Chemotaxis was stimulated with 10 ng/
ml VEGF (VEGF) or complete medium (M199). Migratory 
cells were stained and counted under a light microscope. 
C: Sprouting of HUVEC spheroids embedded into collagen 
gels in the absence (NT) or presence of 10 ng/ml VEGF 
(VEGF). NC, unrelated purified antibodies (500 nM), mAb 
4E1 (500 nM). A representative experiment is shown (original 
magnification, x40). Data represent the ± SD of three-five 
independent experiments each in triplicate.
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Fugure 2: The mAb 4E1 impairs angiogenesis in vivo. 
A: HUVEC were grown on Matrigel in the presence of 
4E1 (500 nM) or unrelated antibodies (NC, 500 nM) and 
the formation of capillary-like structures was observed 
20 h after seeding. A representative experiment is shown 
(original magnification, x100). B: Quantification of tube 
length was performed based on the results shown in 
panel A. Results were expressed as means ± SD of four 
different fields randomly chosen from each group from 
three independent experiments. C: Nude mice were 
injected subcutaneously with Matrigel containing HUVEC 
in the presence of 4E1 or unrelated antibodies (NC). 
Matrigel plugs were excised, sectioned and subjected to 
immunofluorescence analysis. Representative sections, 
stained with anti-von Willebrand factor antibodies, are 
shown. Scale bar represents 150 μm. D: Quantification 
of microvessel density (MVD) was performed based on 
the results shown in panel C as reported in Materials and 
methods. E: Quantification of vessel length was performed 
based on the results shown in panel C as reported in 
Materials and methods. At least ten sections/plug were 
examined. Data represent the ± SD of three independent 
experiments.
Figure 3: The mAb 4E1 recognizes the membrane 
protein CD93 and does not affect endothelial cell 
survival. A: Mouse BALB/c fibroblasts were transfected with 
a construct expressing the human chimeric protein CD93-YFP 
under the control of a constitutive promoter. Cells were plated 
on glass coverslips, fixed and subjected to immunofluorescence 
analysis in the absence of permeabilization by using the mAb 
4E1. Scale bar represents 8 μm. B: Vein section through human 
umbilical cord stained by immunofluorescence using anti-von 
Willebrand factor (von Will) and 4E1 antibodies. The merge of 
the double staining and a DIC image of the same cross section 
are shown. Scale bar, 22 μm. C: The effect of 4E1 treatment 
on survival of growth-arrested endothelial cells. HUVEC 
were grown to confluence and treated with 500 nM of 4E1 or 
unrelated antibodies (NC) for 48 h. The apoptotic percentage 
was calculated by flow cytometric analysis of nuclei stained 
with propidium iodide. D: Cell viability assay on proliferating 
(prolif.) and quiescent (confl.) endothelial cells treated with 
500 nM 4E1 or unrelated antibodies (NC) for 96 h. The optical 
density values were expressed as relative cell viability. All data 
represent the ± SD of three independent experiments.
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even at high concentrations (Fig. 1A). The analysis of cell 
migration by using the Boyden chamber assay showed a 
significant reduction of endothelial cell migration after 
stimulation with growth factors in the presence of 4E1 
compared to control cells (Fig. 1B). Furthermore, the 
ability of HUVEC to sprout up from spheroids embedded 
into collagen gels following VEGF stimulation was 
inhibited almost completely when the spheroids were 
incubated with 4E1, whereas an unrelated antibody did 
not affect significantly sprout number and length (Fig. 
1C), indicating that the mAb 4E1 exerts an antiangiogenic 
effect.
We further investigated the ability of HUVEC to 
form capillary-like structures when cultured on Matrigel, 
which is a process mimicking tube formation during 
angiogenesis in vivo. When HUVEC were grown on 
Matrigel in the presence of 4E1, tubulogenesis was 
strongly impaired with respect to cells grown in the 
presence of an unrelated antibody, since few and broken 
tubes were produced (Fig. 2A and B). Moreover, to assess 
Figure 4: 4E1 recognizes a conformational epitope 
localized on a region overlapping D1 and DX 
domains of CD93. A: Human Lenti-X 293T cells were 
transiently transfected with empty vector (mock) or a 
construct expressing human CD93 full-length. Cell extracts 
were immunoprecipitated with 4E1 and immunoprecipitates 
were analyzed by Western blotting with anti-CD93 antibodies 
(H190). Equal loading of cell lysates was confirmed by using 
anti-β-actin antibodies. B: The schematic diagram illustrates 
the deletion mutants of the CD93 extracellular domains fused 
with a 6X Myc tag. The deletion mutants were designated in 
accordance with Wu and colleagues [15]. LS, signal peptide; 
CTLD, C-type lectin-like domain; X, domain of unknown 
structural function; EGF-like, EGF-like repeats; Mucin mucin-
like domain; Myc, 6X Myc tag. C: Lenti-X 293T cells were 
transiently transfected to generate recombinant CD93 domain 
proteins fused with a 6X Myc tag. For each different deletion 
mutant two different cDNA constructs were transfected (#1 
and #2). Cell extracts were analyzed by immunoblotting using 
anti-Myc antibodies. Anti-β-actin antibodies were used to 
confirm equal loading. D: Cell lysates from cells transfected as 
in C, were subjected to immunoprecipitation analyses by using 
4E1. Immunoprecipitates were analyzed by Western blotting 
with anti-Myc antibodies.
Figure 5: The mAb 4E1 impairs endothelial cell 
adhesion on different substrates. Gelatin (gel), laminin 
(lam) and collagen (coll) adhesive substrates were used 
for coating. HUVEC, grown in complete medium, were 
biochemically detached, incubated in the presence of different 
concentrations of 4E1 (50, 250, and 500 nM) or unrelated 
antibodies (500 nM, NC) for 15 min in ice and allowed to adhere 
on substrate-coated surfaces for 10 min. Fixed cells were stained 
with crystal violet solution, and the optical density values were 
expressed as relative cell adhesion. Data represent the ± SD of 
four independent experiments each in triplicate.
Band AN Protein Peptides Seq. cov. % Score Theor. Mw (Da)
1 Q9NPY3 Complement component C1q receptor 13 26 125 66451
2 Q9NPY3 Complement component C1q receptor 12 25 118 66451
3 Q9NPY3 Complement component C1q receptor 13 27 126 66451
Table I: Protein identification by mass spectrometry. Proteins corresponding to the bands isolated from a gel are indicated. 
AN, accession number retrieved by UniProt knowledgebase (http://www.uniprot.org/). The number of measured peptide 
masses matching the protein, the percentage of the protein sequence covered by the matching peptides (Seq. cov. %), and 
the probabilistic score are shown. Scores greater than 70 are usually considered significant matches. Theor. Mw, theoretical 
molecular weight calculated by Compute pI/Mw tool (http://web.expasy.org/compute_pi/).
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the antiangiogenic effect of 4E1 in vivo, we performed 
a Matrigel plug assay in mice. Exponentially growing 
HUVEC were included in Matrigel in the presence of 
4E1 or an unrelated antibody and injected into nude 
mice. Matrigel plugs were excised and processed for 
immunofluorescence staining (Supplemental Fig. 2). 
Microvessel density and vessel length were determined 
as described in Materials and methods. Importantly, 
microvessel density resulted decreased in plugs containing 
the mAb 4E1 (Fig. 2D) and HUVEC within the plugs 
containing 4E1 significantly decreased their ability to 
form the tubular structures observed in control plugs 
(Fig. 2C and E). Collectively, our data show that the mAb 
4E1 inhibits the formation of new vessels by preventing 
endothelial cell proliferation, migration, and formation of 
capillary-like structures both in vitro and in vivo assays.
CD93 is the target recognized by the mAb 4E1
To unveil the protein recognized by the mAb 
4E1, cell extracts from proliferating HUVEC were 
immunoprecipitated with 4E1 and the electrophoretic 
bands were excised and analyzed by mass spectrometry. 
Three isolated bands corresponded to CD93 also known 
as the complement component C1q receptor (C1qRp) 
(Table I), a type-I transmembrane glycoprotein highly 
expressed on the endothelium. To confirm the binding 
of 4E1 on CD93, we cloned CD93 and expressed the 
protein in mouse BALB/c fibroblasts, which do not 
express endogenous CD93 (Supplemental Fig. 3). 
Immunofluorescence analysis of BALB/c fibroblasts 
transfected with a CD93-YFP plasmid and stained without 
permeabilization by using 4E1 revealed that the CD93-
YFP chimeric protein is detectable both at the cell surface 
and in the cytoplasm whereas 4E1 clearly colocalizes with 
CD93-YFP only to the cellular periphery as shown by the 
merged image (Fig. 3A), showing that 4E1 recognizes 
CD93. 
Since we developed mAbs by immunizing mice with 
exponentially growing HUVEC, we asked whether CD93 
was preferentially expressed in proliferating endothelial 
cells. To address this issue, HUVEC were plated at low 
density, left to grow and maintained at confluence for one 
week. Proteins were extracted at different time-points 
of cell growth and subjected to Western blot analysis. 
Comparison of the protein levels revealed that there 
are no differences in the pattern of expression of CD93 
both in proliferating and resting cells and that CD93 is 
highly expressed in endothelial cells independently of cell 
growth conditions (Supplemental Fig. 4). Accordingly, 
immunofluorescence analysis of umbilical vein sections 
showed that 4E1 staining is localized in endothelial cells 
that lined the interior surface of the cord vessels (Fig. 3B), 
indicating that CD93 is expressed in quiescent endothelial 
cells of healthy blood vessels. For this reason, we asked 
whether the antiangiogenic activity of 4E1 could also exert 
a cytotoxic effect on resting endothelial cells. To address 
this question, HUVEC were grown at confluence for 
few days in the presence of 4E1 or unrelated antibodies 
and subjected to cell survival and viability assays. Flow 
cytometric analysis with propidium iodide staining 
showed that, in cell-cycle arrested endothelial cells 
(Supplemental Fig. 5), the treatment for 48 h with 4E1 
at the higher concentration used for all experiments, does 
not change the percentage of apoptotic cells with respect 
to control cells (Fig. 3C). Moreover, the prolonged 
treatment of endothelial cells with high concentrations of 
4E1 impaired cell viability of proliferating cells, whereas 
the same treatment did not alter cell viability of quiescent 
cells with respect to the control (Fig. 3D). Taken together, 
our results show that the mAb 4E1 binds CD93 and exerts 
its antiangiogenic activity without affecting survival of 
resting endothelial cells.
Mapping of the 4E1 epitope binding site
Since it has been reported that the EGF-like domain 
of CD93 is a potent angiogenic factor, which exerts its 
activity through the binding to EGFR and the activation 
of downstream ERK phosphorylation [15], we asked 
whether 4E1 could interfere with this interaction. To 
address this issue, we proceeded with the identification 
of the binding site of 4E1 on CD93. First, Lenti-X 
293T cells were transfected with CD93 full-length and 
the cell lysates were analyzed by Western blotting and 
immunoprecipitation assays. Whereas the mAb 4E1 
did not show any binding to CD93 by immunoblotting 
analysis under denaturing conditions (data not shown), 
immunoprecipitation with 4E1 and immunoblotting with 
anti-CD93 antibodies revealed that 4E1 is able to bind 
the whole molecule of CD93 from non-denatured cell 
extracts (Fig. 4A), clearly indicating that 4E1 recognizes 
a conformational epitope. Since the structure of human 
CD93 consists of distinct domains [23], we extended 
our mapping analysis generating CD93 deletion mutants 
and testing the ability of 4E1 to immunoprecipitate these 
recombinant proteins (Fig. 4B). Each chimeric mutant 
was fused with the Myc epitope tag and two different 
constructs were transfected in Lenti-X 293T cells, which 
do not express wild-type CD93 (Fig. 4A). Then, mutant 
expression was checked by Western blotting analysis 
with anti-Myc antibodies (Fig. 4C). Immunoprecipitation 
analyses of the deletion constructs allowed us restricting 
the region of CD93 containing the epitope recognized by 
4E1 to a region overlapping the domains D1 and DX, with 
both extracellular domains necessary to fold the epitope 
correctly (Fig. 4D). Accordingly, we observed that 4E1 
does not interfere with the CD93-dependent activation of 
ERK1/2 (Supplemental Fig. 6), which has been previously 
shown to be dependent on the EGF-like domain of CD93 
[15]. Instead, in agreement with a possible involvement 
of CD93 in endothelial cell adhesion and migration [16, 
Oncotarget2755www.impactjournals.com/oncotarget
19], we observed that 4E1 is able to inhibit endothelial 
cell attachment to different adhesive substrates in a dose-
dependent manner (Fig. 5), suggesting that inhibition of 
cell adhesion is the inhibitory effect exerted on endothelial 
cells by 4E1.
CD93 knockdown impairs endothelial cell 
function
To further investigate the involvement of CD93 
in the regulation of the angiogenic process, we silenced 
CD93 in HUVEC by two lentiviral constructs expressing 
two independent CD93 shRNAs (clones 85 and 86). 
HUVEC infected with lentiviruses expressing either 
CD93 shRNA showed reduced CD93 protein levels while 
no CD93 reduction was revealed upon infection with a 
lentivirus expressing an unrelated shRNA (Fig. 6A). Since 
in response to proangiogenic stimuli quiescent endothelial 
cells become activated and involved in proliferation, 
migration, and differentiation, we assessed the effect of 
CD93 silencing in growth factor-stimulated endothelial 
cells. First, we observed that DNA synthesis, determined 
by thymidine uptake, is strongly decreased in growth 
factor-induced endothelial cells expressing CD93 shRNAs 
with respect to control cells (Fig. 6B). Furthermore, cell 
adhesion and VEGF-stimulated migration of endothelial 
cells silenced for CD93 resulted significantly decreased 
compared to control cells expressing an unrelated shRNA 
(Fig. 6C and 6D). Finally, the ability of HUVEC to form 
VEGF-induced sprouts from spheroids embedded into 
collagen gels was nearly totally inhibited when endothelial 
Figure 6: CD93 silencing affects cell proliferation, adhesion, migration, and in vitro sprouting of human endothelial 
cells. HUVEC were infected with a lentiviral vector expressing unrelated (unr) or CD93 shRNAs (clone 85 or 86). A: Cell extracts from 
shRNA expressing HUVEC were analyzed by Western blotting using anti-CD93 (H190) and anti-β-actin antibodies to confirm equal 
loading. B: Cell proliferation expressed as thymidine uptake in infected HUVEC. Cells were grown in 96-well-plates, serum starved (starv) 
and induced with complete medium (induct). Not infected endothelial cells were also analyzed (-). C: Cell adhesion assay of infected 
HUVEC. Cells were biochemically detached and allowed to adhere on gelatin-coated surfaces for 15 min. Fixed cells were stained with 
crystal violet solution and the optical density values were expressed as relative cell adhesion. D: Migration assay on infected HUVEC. Cells 
were grown in growth factor-depleted culture medium and plated in Boyden chambers. Chemotaxis was stimulated with 10 ng/ml VEGF. 
Migratory cells were stained and counted under a light microscope. E: Sprouting assay of infected endothelial cells embedded into collagen 
gels in the absence (NT) or presence of 10 ng/ml VEGF (VEGF). A representative experiment is shown (original magnification, x40). Data 
represent the ± SD of four-five independent experiments each in triplicate.
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cells were transduced with lentiviruses carrying CD93 
shRNAs, while sprouting was not impaired in HUVEC 
infected with lentiviruses carrying the control shRNA 
(Fig. 6E). Taken together these results indicate that CD93 
plays a role in endothelial cell proliferation and migration 
to control the organization of endothelial cells into vessel 
structures. 
DISCUSSION
In this report, we characterize a novel antiangiogenic 
antibody, designated as 4E1. We showed that treatment 
with 4E1 impairs proliferation, migration, and sprouting 
of human endothelial cells. Murine angiogenesis assays 
confirmed that 4E1 is able to halt angiogenesis in vivo, 
demonstrating that 4E1 neutralizes an antigen exposed on 
endothelial cells that is involved in the regulation of the 
angiogenic process. By mass spectrometry we identified 
this antigen as CD93. 
Our study supports a model positing that CD93 is 
involved in the regulation of endothelial cell function 
during angiogenesis. Indeed, by RNA interference we 
showed that in endothelial cells CD93 knockdown 
strongly affects proliferation, migration, and formation 
of capillary-like structures. CD93 is an adhesion 
molecule involved in biological processes that require 
dynamic cytoskeletal rearrangement such as migration 
[24]. Moreover, the linkage of CD93 to actin by Moesin 
contributes to a redistribution of the cytoskeleton that has 
been shown to be essential for migration and adhesion 
[23]. Consistent with these observations, we observed 
that CD93 has a pattern of localization similar to Moesin, 
being mainly concentrated in the apical domain of 
adhering endothelial cells (data not shown) [25], 4E1 
is able to inhibit endothelial cell adhesion on different 
substrates, and CD93 silencing impairs cell attachment to 
the substrate, suggesting a role for CD93 in adhesion of 
endothelial cells.
Although CD93 is predominantly expressed in the 
endothelium of mouse and human origin [16, 19], CD93-
deficient mice are viable and show no gross abnormalities 
in their vascular development [26]. This discrepancy could 
be explained by gene compensations in the knockout 
animals, as observed with other genes [27], because CD93 
belongs to a family of transmembrane glycoproteins, 
which also includes endosialin and thrombomodulin [24].
It has been reported that soluble CD93 fragments 
are released during inflammation and their presence in 
the plasma of patients is a biomarker for coronary artery 
disease [28, 29]. Soluble CD93 may be the product of 
ectodomain cleavage of membrane CD93 mediated 
by matrix metalloproteinases, known to be key factors 
in vascular remodeling [20]. Moreover, the EGF-like 
domain of soluble CD93 has recently been shown to 
exhibit proangiogenic effects on the endothelium acting 
as an EGFR agonist [15]. In agreement with our mapping 
studies, which localized the 4E1 epitope on CD93 outside 
the EGF-like domain, we found that 4E1 does not impair 
CD93-dependent EGFR activation. Taken together, these 
results suggest that CD93 plays different angiogenic 
functions both as membrane-intercalated protein or soluble 
fragments and 4E1 can discriminate between them.
As selection for resistance is a hallmark of an 
effective antiangiogenic therapy and a consequence of 
tumor regression, for improving the treatment of human 
cancer with angiogenesis inhibitors, a promising strategy 
involves multi-targeting of parallel proangiogenic 
signaling pathways to circumvent evasive mechanisms 
[7, 8]. Thus, the neutralization of CD93 in combination 
with other drugs or blocking agents could be revealed 
instrumental in antiangiogenic treatment of cancer. 
Importantly, endothelial cell survival and viability of 
quiescent cells were not affected by 4E1 treatment. 
Although 4E1 was raised in mice using exponentially 
growing HUVEC, we found that CD93 is expressed at 
the same levels both in growing and quiescent cells but 
4E1 is able to specifically affect only proliferating cells, 
suggesting that CD93 plays its angiogenic function when 
endothelial cells shuttle from a quiescent to a proliferating 
state. Consistent with these results, in matrigel plug 
assays microvessel density, in which isolated cells 
were considered as a vessel, resulted slightly decreased 
indicating that 4E1 targeting CD93 inhibits branching of 
new vessels but not survival of endothelial cells localized 
in the plug. In conclusion, our results suggest that CD93 
represents a new antigen on endothelial cells, whose 
targeting may be an useful tool to halt angiogenesis.
MATERIALS AND METHODS
Cell culture and transfections
HUVEC were isolated from umbilical cords 
collected from uncomplicated pregnancies of consenting 
healthy patients. For each experiment at least three 
independent extractions of HUVEC were used. Cells 
were cultured on gelatin-coated Petri dishes in 1:1 (v/v) 
M199 (containing 20% fetal bovine serum and 100 µg/
mL brain extract) and EBM-2 with supplements (Lonza, 
Basel, Switzerland) culture media and used in passages 
3-6. Mouse BALB/c (ATCC, Manassas, VA, USA) and 
human Lenti-X 293T (Clontech Lab, Mountain View, CA, 
USA) cell lines were cultured using standard conditions. 
Transient transfection experiments were performed by 
using PolyFect reagent (Qiagen, Hilden, Germany) in 
BALB/c cells and lipofectamine 2000 (Invitrogen, San 
Diego, CA, USA) in Lenti-X 293T cells according to 
instructions from the manufacturers.
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Monoclonal antibody production
mAbs were generated as previously described [30]. 
Briefly, female BALB/c mice were fourfold injected with 
8 x 106 cultured HUVEC released from the substrate 
by using detaching buffer (10 mM EDTA in PBS) and 
resuspended as single cells in PBS. Immune spleen 
cells were fused with X63-Ag8 myeloma cells. 1021 
hybridomas were screened for their ability to produce 
mAbs that bind endothelial cell surface antigens by 
flow cytometry. Briefly, after biochemical detachment, 
HUVEC were incubated in PBS containing 5% fetal 
bovine serum to block unspecific binding and labeled 
with primary antibodies diluted in PBS containing 1% 
bovine serum albumin. Staining was revealed using anti-
mouse conjugated secondary antibodies. Then, positive 
mAbs were selected for their ability to not recognize 
antigens expressed on the surface of human epithelial 
HEK-293 cells (ATCC). Data acquisition and analysis 
were performed in a Becton Dickinson FACS Calibur 
flow cytometer using CellQuest software. 61 different 
antibodies that recognized endothelial surface molecules 
were purified by affinity chromatography with HiTrap 
Protein G columns (GE Healthcare, Piscataway, NJ, USA) 
and used in inhibition assays.
Cell proliferation, cell viability, apoptosis, 
migration, adhesion, and in vitro angiogenesis 
assays
Cell proliferation was evaluated by thymidine 
incorporation as previously described [30]. Cell viability 
was quantified by spectrophotometric measurement of 
the mitochondrial dehydrogenase activity by using the 
CellTiter 96® AQueous one solution cell proliferation kit 
(Promega, Fitchburg, WI, USA) according to manufacturer 
instructions. The optical density values were measured at 
490 nm using a microtiter plate reader (VERSAmax™, 
Molecular Devices, Sunnyvale, CA, USA). The percentage 
of apoptotic nuclei was assessed as previously described 
by propidium iodide staining followed by flow cytometric 
analysis [31]. For adhesion assays, the following adhesive 
substrates were dissolved in PBS and used for coating of 
96-well plates (2h at 370 C): rat collagen (mainly type I 
collagen, 10 µg/mL) from Roche Diagnostics (Mannheim, 
Germany), porcine gelatin (1%) and mouse laminin (10 
g/mL) from Sigma-Aldrich. Nonspecific adhesion was 
blocked with M199 culture medium containing 3% bovine 
serum albumin. 2.5 x 104 HUVEC, grown in complete 
medium, were biochemically detached, and allowed to 
adhere on substrate-coated surfaces. 10 min after plating, 
cells were fixed in 3% paraformaldehyde, stained with 
0.05% (w/v) crystal violet solution, and the optical 
density values were measured at 570 nm. Chemotaxis 
analysis with Boyden transwell chambers, endothelial 
cell sprouting assay in collagen gels and formation of 
capillary-like tube structures in Matrigel were performed 
as previously described [32, 33]. For neutralization assays, 
the mAb 4E1 was used at different concentrations based 
on available dosing schedules previously used for other 
antiangiogenic antibodies targeting surface proteins not 
belonging to the VEGF family [34, 35]. 
Matrigel plug assay
Female 10-week-old nude mice were obtained from 
Charles River (Wilmington, MA, USA). The mice were 
Table II: Deletion mutants of CD93 extracellular domains. The recombinant domain proteins 
of CD93 cover the amino acid sequence reported (a.a.). The protein sequence of human CD93 
is numbered according to the sequence with GenBank™ accession number AAH28075.1. cDNA 
fragments were PCR-amplified by using the forward and reverse primers indicated (oligos).
CD93 domains a.a. oligos
CD93D1X23 M1-K580 P389 GAGAggatccGCCGCCACCGGGATGG forP390 GAGAggatccCTTTTGCCCGTCAGTGC rev
CD93D1X2 M1-G470 P389 forP394 GAGAggatccCCCCATGGTGCAAGAGAC rev
CD93D23 V258-K580 P397 GAGAggatccGTCAGCCCCAAGTATGG forP390 rev
CD93D1 M1-G177 P389 forP393 GAGAggatccGCCCTCAATGTTACTTCC rev
CD93DX2 F178-G470 P434 GAGAggatccTTCGTGTGCAAGTTCAGC forP394 rev
CD93D1X M1-C257 P389 forP433 GAGAggatccACAGAGGGGGCCCGAG rev
CD93DX F178-C257 P434 forP433 rev
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subcutaneously injected in the dorsal region with 500 µL 
of growth factor reduced Matrigel (BD Biosciences, San 
Jose, CA, USA) mixed 2:1 (v/v) with HUVEC (6 x 106 
cells/mL). For assays with neutralizing antibody, the mAb 
4E1 was incorporated into the Matrigel. Matrigel plugs 
were surgically removed after 2 weeks, embedded in OCT, 
cryostat sectioned and processed for immunofluorescence 
analysis. For evaluation of microvessel density, areas 
with the highest microvessel concentration were visually 
identified and several histological fields were chosen 
for the measurement. The area of the histological fields 
was 533,448 µm2 (20x objective lens and 10x ocular 
lens). Isolated cells or clusters of cells displaying a 
strong fluorescent staining were considered as a vessel. 
Quantitative analysis of digital images was performed 
using ImageJ software. The number of von Willebrand 
factor-positive structures was counted in a minimum 
of five fields/section. The mean vessel length/field was 
calculated in ten fields/section. Statistical significance of 
the data was evaluated using an unpaired Student’s t-test.
Immunofluorescence microscopy
For histological analysis, C57BL/6 mice were 
sacrificed and portions of tail were dissected and frozen in 
liquid nitrogen. Portions of human umbilical cords were 
dissected and frozen in liquid nitrogen. 10 µm cryostat 
sections from tails, umbilical cords or Matrigel plugs 
were fixed in 3% paraformaldehyde for 15 min at room 
temperature. Cells were seeded onto gelatin-coated glass 
coverslips and fixed in 3% paraformaldehyde. Histological 
sections and cells were treated as previously described 
[33, 36]. The following primary antibodies were used: 
mouse anti-CD93 (mAb 4E1, 0.6 mg/mL) 1:25; rabbit 
anti-von Willebrand factor (Dako, Glostrup, Denmark); 
rat anti-CD31 (BD Pharmingen, San Diego, CA, USA). 
Fluorescent images were captured using a Leica TCS SP2 
laser-scanning confocal microscope.
Cloning and plasmid constructs
The full-length cDNA of human CD93 (GenBank 
accession number NM_012072.3) was amplified 
using the BcaBEST RNA PCR kit (Takara Bio Inc., 
Otsu, Japan) from reverse transcription of total RNA 
extracted from HUVEC (oligonucleotides CD93F,5’-
GAGAGGATCCGCCGCCACCGGGATGGCCACCT-3’ 
and CD93R, 5’-GAGAGAGCGGCCGCCTCTAG 
GGCCACCTCAC-3’. The PCR fragments were cloned 
in pcDNA3 cloning vector (Invitrogen). CD93 full-length 
cDNA was subcloned into pEYFP-N1 vector (Clontech 
Lab), positioning the fluorescence tag at C-terminal. 
To generate the chimeric constructs containing the 
extracellular domains of CD93 fused to Myc tag, DNA 
fragments were PCR-amplified from a cDNA clone 
corresponding to the complete sequence of the human 
CD93 gene and cloned in pCS2+myc tag vector [37]. 
The chimeric constructs and the primers used for DNA 
amplification are reported in Table II. All constructs were 
confirmed by sequencing.
Mass spectrometry
Protein identification was carried out by peptide 
mass fingerprinting on an Ultraflex III MALDI-TOF/TOF 
mass spectrometer (Bruker Daltonics, Billerica, MA), as 
previously described [38].
RNA interference-mediated knockdown of CD93
Silencing experiments were performed using 
retroviral vectors pLKO.1 from the TRC lentiviral 
shRNA library (Open Biosystems, Huntsville, AL, 
USA) expressing specific shRNAs for human CD93 
(oligonucleotide TRCN0000029085, designated as 85; 
and oligonucleotide TRCN0000029086, designated as 
86). Recombinant lentiviruses were produced and used for 
infection experiments as previously described [33]. 
Immunoprecipitation and immunoblotting 
analyses
Immunoprecipitation and immunoblotting 
analyses were performed as previously described 
[33]. The following primary antibodies were used for 
immunoblotting: rabbit anti-CD93 (H190) and mouse 
anti-c-Myc (9E10, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA); mouse anti-β-actin (Sigma-Aldrich, St Louis, 
MO, USA); anti-p44/42 MAPK and anti-phospho-p44/42 
MAPK (Cell Signaling, Danvers, MA, USA). For 
immunoprecipitations, the protein extracts were incubated 
for 2 h at 4° C with the mAb 4E1 coupled to Dynabeads® 
Pan Mouse IgG (Invitrogen).
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